Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 37

References for PMC Articles for PubMed (Select 19015565)

1.
2.

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL.

Ann Intern Med. 2007 Nov 20;147(10):677-84.

PMID:
18025443
3.

Social costs of robbery and the cost-effectiveness of substance abuse treatment.

Basu A, Paltiel AD, Pollack HA.

Health Econ. 2008 Aug;17(8):927-46.

4.

Correlates of consistent condom use with main partners by partnership patterns among young adult male injection drug users from five US cities.

Kapadia F, Latka MH, Hudson SM, Golub ET, Campbell JV, Bailey S, Frye V, Garfein RS; DUIT Study Team.

Drug Alcohol Depend. 2007 Nov;91 Suppl 1:S56-63. Epub 2007 Feb 27.

PMID:
17329041
5.

Changes in injecting practices associated with the use of a medically supervised safer injection facility.

Stoltz JA, Wood E, Small W, Li K, Tyndall M, Montaner J, Kerr T.

J Public Health (Oxf). 2007 Mar;29(1):35-9. Epub 2007 Jan 17.

6.

Survival of persons with and without HIV infection in Denmark, 1995-2005.

Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT, Vaeth M, Obel N.

Ann Intern Med. 2007 Jan 16;146(2):87-95.

PMID:
17227932
7.

Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study.

Vickerman P, Hickman M, Judd A.

Int J Epidemiol. 2007 Apr;36(2):396-405. Epub 2007 Jan 11.

8.

Summary of findings from the evaluation of a pilot medically supervised safer injecting facility.

Wood E, Tyndall MW, Montaner JS, Kerr T.

CMAJ. 2006 Nov 21;175(11):1399-404.

9.

The lifetime cost of current human immunodeficiency virus care in the United States.

Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR 3rd, Moore RD, Freedberg KA.

Med Care. 2006 Nov;44(11):990-7. Review.

PMID:
17063130
10.

The direct costs of HIV/AIDS care.

Levy AR, James D, Johnston KM, Hogg RS, Harrigan PR, Harrigan BP, Sobolev B, Montaner JS.

Lancet Infect Dis. 2006 Mar;6(3):171-7. Review.

PMID:
16500598
11.

Hepatitis C transmission -- where are we now?

Clarke A, Kulasegaram R.

Int J STD AIDS. 2006 Feb;17(2):74-80; quiz 80. Review.

PMID:
16464265
12.

Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART.

Lumbreras B, Jarrín I, del Amo J, Pérez-Hoyos S, Muga R, García-de la Hera M, Ferreros I, Sanvisens A, Hurtado I, Hernández-Aguado I.

AIDS. 2006 Jan 2;20(1):111-6.

PMID:
16327326
13.

Prevalence and correlates of hepatitis C infection among users of North America's first medically supervised safer injection facility.

Wood E, Kerr T, Stoltz J, Qui Z, Zhang R, Montaner JS, Tyndall MW.

Public Health. 2005 Dec;119(12):1111-5. Epub 2005 Oct 7.

PMID:
16214189
14.

Survey of drug consumption rooms: service delivery and perceived public health and amenity impact.

Kimber J, Dolan K, Wodak A.

Drug Alcohol Rev. 2005 Jan;24(1):21-4.

PMID:
16191717
15.

Safer injection facility use and syringe sharing in injection drug users.

Kerr T, Tyndall M, Li K, Montaner J, Wood E.

Lancet. 2005 Jul 23-29;366(9482):316-8.

PMID:
16039335
16.

Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver.

Kerr T, Marsh D, Li K, Montaner J, Wood E.

Drug Alcohol Depend. 2005 Dec 12;80(3):329-35. Epub 2005 Jun 17.

PMID:
15964714
17.

A description of a peer-run supervised injection site for injection drug users.

Kerr T, Oleson M, Tyndall MW, Montaner J, Wood E.

J Urban Health. 2005 Jun;82(2):267-75. Epub 2005 May 4.

18.

Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada.

Krahn MD, John-Baptiste A, Yi Q, Doria A, Remis RS, Ritvo P, Friedman S.

Vaccine. 2005 Feb 18;23(13):1549-58.

PMID:
15694507
19.

Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users.

Wood E, Kerr T, Lloyd-Smith E, Buchner C, Marsh DC, Montaner JS, Tyndall MW.

Harm Reduct J. 2004 Nov 9;1(1):9.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk